Steven M. Devine on Muck Rack

Steven M. Devine

Verified
Ottawa
As seen in: WCMY-AM (Ottawa, IL), Nature, Wiley Online Library, MDPI, The Hill, JAMA (The Journal of the American Medical Association), JAMA Network, MedCity News, medRxiv, Blood, ONCOLOGY journal and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Steven M.

Contact Steven M., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Measurable residual mutated NPM1 before allogeneic transplant for acute myeloid leukemia - Bone Marrow Transplantation

|
By Niveditha Ravindra, Jeffery J. Auletta, Firas El Chaer, Steven M. Devine Verified, Mark Litzow, Partow Kebriaei, Jerald P. Radich, Laura Dillon
| Nature Verified
NPM1 mutations (NPM1m), seen in ~30% of adults with acute myeloid leukemia (AML), often co-occur with FLT3 internal tandem duplication (FLT3-ITD) [1, 2]. Measurable residual disease (MRD) testing in first complete remission (CR) identifies patients at high risk of relapse after allogeneic hematopoietic cell transplantation (alloHCT) [3, 4].
Open in Who Shared Issue with article?

Measurable residual mutated IDH1 before allogeneic transplant for acute myeloid leukemia - Bone Marrow Transplantation

|
By Niveditha Ravindra, Zoe Bayliss Wong, Zoë C Wong, Jeffery J. Auletta, Yi-Bin Chen, Steven M. Devine Verified, Mark Litzow, Partow Kebriaei, Stephen Spellman, Laura Dillon
| Nature Verified
Abstract Measurable residual disease (MRD) in adults with acute myeloid leukemia (AML) in complete remission is an important prognostic marker, but detection methodology requires optimization. Persistence of mutated NPM1 or FLT3-ITD in the blood of adult patients with AML in first complete remission (CR1) prior to allogeneic hematopoietic cell transplant (alloHCT) associates with increased relapse and death after transplant.
Open in Who Shared Issue with article?

Measurable residual mutated IDH2 before allogeneic transplant for acute myeloid leukemia - Bone Marrow Transplantation

|
By Niveditha Ravindra, Zoe Bayliss Wong, Zoë C Wong, Jeffery J. Auletta, Yi-Bin Chen, Steven M. Devine Verified, Mark Litzow, Partow Kebriaei, Stephen Spellman, Laura Dillon
| Nature Verified
Abstract Routine genetic profiling of acute myeloid leukemia (AML) at initial diagnosis has allowed subgroup specific prognostication, drug development, and clinical management strategies. The optimal approach for treatment response assessment for AML subgroups has not yet however been determined.
Open in Who Shared Issue with article?
See all 1,402 licensed articles (1,405 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified